Herbal Supplement Prosta-OK® Neo as an Adjunct Therapy in Patients With Mild to Severe Non-neurogenic Male Lower Urinary Tract Symptoms Receiving Tamsulosin Therapy

Acrobio Healthcare

Status: Unknown

Conditions: Lower Urinary Tract Symptoms

Treatments: Dietary Supplement: Prosta-OK® Neo or Prosta-OK® Neo-matched placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT04418635

LPO201910

Details and patient eligibility

About

The aim of the study is to uses Prosta-OK® Neo that contains herb extracts including lycopene, phellinus linteus, pomegranate, pumpkin seed, selenium and zinc that have been demonstrated with functions of inhibiting 5-alpha reductase, antioxidant, anti-inflammation and regulating the synthesis of nitric oxide to explore whether Prosta-OK® can help reduce symptoms and elevate the quality of life in patients with mild to severe non-neurogenic male lower urinary tract symptoms receiving Tamsulosin therapy.

Full description

Lower urinary tract symptoms (LUTS) are kind of uncomfortable subjective feelings reported from patients and are divided into three groups, storage, voiding, and postmicturition symptoms. Many epidemiological studies have pointed out that the prevalence of LUTS among individuals aged at least 40 years in the United States, the United Kingdom, Sweden, China, Taiwan, and South Korea is up to 60%. LUTS may cause mental health disorders such as anxiety and depression and affect lifestyle that leads to a negative impact on the quality of life. In recent years, there have been numerous academic or clinical studies that assess the improvement of plant and herb extracts in LUTS.

Prosta-OK® Neo is mainly comprised of herb extracts, including lycopene, phellinus linteus, pomegranate, pumpkin seed, selenium and zinc that have been demonstrated with functions of inhibiting 5-alpha reductase, antioxidant, anti-inflammation and regulating the synthesis of nitric oxide.

The aim of the study is to explore whether take Prosta-OK® 2 tablets for 85 days compared with placebo group can help reduce symptoms and elevate the quality of life in patients with mild to severe non-neurogenic male LUTS receiving Tamsulosin therapy.

Enrollment: 100 estimated patients

Sex: Male

Ages: 30 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• male between the ages of 30 and 55 when signing the informed consent form
• the subject was diagnosed with mild to severe non-neurogenic lower urinary tract symptoms and planed to receive Tamsulosin therapy
• the sum of International Prostate Symptom Score (IPSS) on questions 1 to 7 was 10 points or higher
• the subject can take medication via oral or nasogastric tube confirmed with the function of absorption by the principal investigator or co-principal investigators
• the subject was willing to corporate study-related procedures and sign the informed consent form

Exclusion criteria

• post-void residual urine volume greater than 200 mL or peak of maximum urine flow rate less than 5 mL/s
• total serum prostate-specific antigen higher than 10 ng/mL
• bladder outlet obstruction caused by reasons other than benign prostatic hyperplasia
• lower urinary tract symptoms caused by neurological disease such as Cerebrovascular Diseases, Parkinson's, dementia, Multiple Sclerosis (MS), spinal cord injuries (SCI), cauda equina syndrome, and Peripheral Neuropathy
• history or evidence of prostate cancer, male reproductive cancers, bladder cancer, and cancer of the ureter and urethra
• history or evidence of acute urinary retention (AUR)
• history or evidence of acute orthostatic hypotension
• with the urinary catheter or intermittent catheter
• stone in the urinary system
• Interstitial cystitis (IC), neurogenic bladder, overactive bladder (OAB) and Inflammatory Bowel Disease (IBD) within 3 mo prior to study entry
• chemotherapy or radiation therapy within 3 mo prior to study entry
• immunosuppressive therapy within 2 mo prior to study entry
• pelvic surgery or urinary surgery within 2 mo prior to study entry
• 5-alpha-reductase inhibitors use within 6 mo prior to entry or alpha-1-adrenergic blockers use within 2 w prior to entry
• the subject plans to use medication other than Tamsulosin such as alpha-blocker, 5-alpha-reductase inhibitors, antimuscarinic drugs, phosphodiesterase type 5 inhibitor (PDE5 inhibitors), Beta-3 agonists, desmopressin, diuretics, phenazopyridine, other drugs or foods are known to interact with tamsulosin and steroid or a nonsteroidal anti-inflammatory drug during participating in the study.
• the subject plans to receive cataract surgery during participating in the study or 1 mo after participating in the study.
• the subject took other therapies such as acupuncture or phytotherapy, including Saw Palmetto, Pygeum Africanum, Hypoxis Rooperi, Rye-pollen extract, and Pumpkin Seed extract within 2 w prior to entry.
• the subject took Chinese herbs such as Soaring Dragon Decoction, Rehmannia Right Formula, Powder for Five Types of Painful Urinary Dysfunction, Minor Bupleurum Decoction, Artemisiae Scopariae Decoction, Decoction to Enrich Yin and Direct Fire Downward, Tonifies Qi、Coptis Decoction to Relieve Toxicity and related modifications, Radix Rehmanniae, Cortex Moutan, Radix Pulsatillae, Herba Taraxaci, Herba Portulacae, Fructus Forsythiae, Flos Lonicerae, Herba Lophatheri, Fructus Gardeniae, Phellinus linteus within 7 days prior to entry.
• have a history of allergy to the ingredients of investigational product
• Serum Glutamic-Oxaloacetic Transaminase and serum Glutamic-Pyruvic Transaminase were more than three times of normal range or Serum creatinine less than 1.5 mg/dL
• have a history of substance abuse within 2 yr prior to entry
• participating in any clinical trial such as health food, herbal extracts, and drug within 30 days prior to entry
• have other significant diseases and confirmed by the principal investigator as non-eligible to be enrolled in the study

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

100 participants in 2 patient groups, including a placebo group

Tamsulosin and Prosta-OK® Neo

Experimental group

Description:

Tamsulosin 0.2mg once daily and Prosta-OK® Neo 707mg 2 tablets twice daily for 85 days

Treatment:

Dietary Supplement: Prosta-OK® Neo or Prosta-OK® Neo-matched placebo

Tamsulosin and Prosta-OK® Neo-matched placebo

Placebo Comparator group

Description:

Tamsulosin 0.2mg once daily and Prosta-OK® Neo-matched placebo 707mg 2 tablets twice daily for 85 days

Treatment:

Dietary Supplement: Prosta-OK® Neo or Prosta-OK® Neo-matched placebo